Very interesting new study about how “taking” butyrate as a dietary supplement might help reduce the inflammation and tissue damage seen in rheumatoid arthritis.
An even more effective way to increase butyrate levels may be “making” it yourself via your own microbiome. Several studies have shown this – including a few of ours on Fundamentals – that we can nourish the microbiome with the right “biotics” (probiotics, prebiotics, postbiotics, and phytobiotics) to significantly increase our internal production of butyrate. The benefits include better mood, higher energy, sharper focus, better immune function, and even weight loss – it’s pretty miraculous what this little microbiome-derived molecule can do – and Amare is the only company with products that allow you to “take” butyrate (MentaSync) as well as “make” more of your own butyrate (Fundamentals and Kids Fundamentals).
Gut microbiome butyrate and rheumatoid arthritis
Researchers at Peking University People’s Hospital in Beijing and the Chinese Academy of Sciences have identified an intestinal imbalance in the microbiomes of people who suffer from rheumatoid arthritis linked to the levels of a short-chain fatty acid known as butyrate. Sequencing the gut bacteria of 25 people with untreated rheumatoid arthritis and comparing them to 29 people without the disease, they found people with the disease have lower levels of a number of bacterial species producing butyrate—and elevated levels of bacteria that metabolize it. They showed that feeding mice dietary butyrate supplements reduced aspects of the disease, suggesting the potential for butyrate supplementation therapy for people with rheumatoid arthritis.
Intestinal butyrate-metabolizing species contribute to autoantibody production and bone erosion in rheumatoid arthritis
. 2022 Feb 11;8(6):eabm1511.
doi: 10.1126/sciadv.abm1511. Epub 2022 Feb 11.
Jing He 1 2 , Yanan Chu 3 , Jing Li 1 2 , Qingren Meng 4 , Yudong Liu 5 , Jiayang Jin 1 2 , Yifan Wang 1 2 , Jian Wang 3 , Bo Huang 1 2 , Lianjie Shi 1 2 , Xing Shi 6 , Jiayi Tian 1 2 , Yunzhi Zhufeng 1 2 , Ruiling Feng 1 2 , Wenjing Xiao 1 2 , Yuzhou Gan 1 2 , Jianping Guo 1 2 , Changjun Shao 3 , Yin Su 1 2 , Fanlei Hu 1 2 , Xiaolin Sun 1 2 , Jun Yu 7 , Yu Kang 3 , Zhanguo Li 1 2 8
- PMID: 35148177
- DOI: 10.1126/sciadv.abm1511
The imbalance between pathogenic and beneficial species of the intestinal microbiome and metabolism in rheumatoid arthritis (RA) remains unclarified. Here, using shotgun-based metagenome sequencing for a treatment-naïve patient cohort and a “quasi-paired cohort” method, we observed a deficiency of butyrate-producing species and an overwhelming number of butyrate consumers in RA patients. These outcomes mainly occurred in patients with positive ACPA, with a mean AUC of 0.94. This panel was also validated in established RA with an AUC of 0.986 in those with joint deformity. In addition, we showed that butyrate promoted Tregs, while suppressing Tconvs and osteoclasts, due to potentiation of the reduction in HDAC expression and down-regulation of proinflammatory cytokine genes. Dietary butyrate supplementation conferred anti-inflammatory benefits in a mouse model by rebalancing TFH cells and Tregs, as well as reducing antibody production. These findings reveal the critical role of butyrate-metabolizing species and suggest the potential of butyrate-based therapies for RA patients.